Juvenile Diabetes Research Foundation (JDRF): Novel Immune Strategies to Enhance Beta Cell Replacement Therapies for T1D (LOI)

Letters of intent (LOI’s) are sought for preclinical and/or clinical studies from academic or industry applicants with innovative and incremental immune modulation and engineering approaches aiming to effectively subvert and/or modulate undesired immune reactivity against implanted cells products towards more tolerogenic responses in vivo. Collaborations including complementary expertise i.e. bioengineers, immunologists, cell biologists, transplant researchers, are highly encouraged and will be prioritized. Only projects with relevance to T1D will be considered.

The maximum funding request is $350,000 per year over a maximum duration of two years. Proposals may also be submitted for pilot projects and feasibility studies, without significant preliminary data, up to a total of $150,000 over one year.

https://grantcenter.jdrf.org/rfa/novel-immune-strategies-to-enhance-beta-cell-replacement-therapies-for-t1d/